NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of Argos
Therapeutics, Inc. (NASDAQ:ARGS). On February 17, 2017, Momenta
announced that a contracted Pfizer facility used to manufacture the
Company's Glatopa product had received a warning letter from the U.S.
Food and Drug Administration. The Company’s Abbreviated New Drug
Application (ANDA) for its Glatopa 40 mg product candidate is still
under regulatory review, with final approval reliant upon the acceptable
resolution of the compliance observations at the Pfizer manufacturing
facility. In an earnings call on February 21, 2017, Momenta President
and CEO Craig Wheeler stated that, as a result of the warning letter,
“it is unlikely that Sandoz’s ANDA for Glatopa 40 mg will be approved in
the first quarter of 2017.” To obtain additional information, go to:

“it is unlikely that Sandoz’s ANDA for Glatopa 40 mg will be approved in
the first quarter of 2017.”

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New
Jersey, California, Connecticut, and Washington D.C. The firm’s
attorneys have extensive expertise and experience representing investors
in securities litigation involving financial fraud, and have recovered
hundreds of millions of dollars for aggrieved shareholders. Attorney
advertising. Prior results do not guarantee similar outcomes.